112 related articles for article (PubMed ID: 11599800)
1. Serum matrix metalloproteinase-2 in patients with malignant melanoma.
Wollina U; Hipler UC; Knöll B; Graefe T; Kaatz M; Kirsch K
J Cancer Res Clin Oncol; 2001 Oct; 127(10):631-5. PubMed ID: 11599800
[TBL] [Abstract][Full Text] [Related]
2. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
3. Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma.
Vuoristo MS; Kellokumpu-Lehtinen P; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E; Laine S
Acta Oncol; 2000; 39(7):877-9. PubMed ID: 11145448
[TBL] [Abstract][Full Text] [Related]
4. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma.
Tas F; Duranyildiz D; Oguz H; Disci R; Kurul S; Yasasever V; Topuz E
Med Oncol; 2005; 22(1):39-44. PubMed ID: 15750195
[TBL] [Abstract][Full Text] [Related]
5. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
6. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
7. Immunolocalisation studies of matrix metalloproteinases-1, -2 and -3 in human melanoma.
Walker RA; Woolley DE
Virchows Arch; 1999 Dec; 435(6):574-9. PubMed ID: 10628799
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous measurement of circulating intercellular adhesion molecule-1 and serum copper zinc superoxide dismutase activity in patients with malignant melanoma.
Wollina U; Karte K; Olbertz K; Hipler UC
Oncol Rep; 1998; 5(2):473-6. PubMed ID: 9468582
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma.
Yoshino Y; Kageshita T; Nakajima M; Funakubo M; Ihn H
J Dermatol; 2008 Apr; 35(4):206-14. PubMed ID: 18419677
[TBL] [Abstract][Full Text] [Related]
10. Coordinate expression of membrane type-matrix metalloproteinases-2 and 3 (MT2-MMP and MT3-MMP) and matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells.
Ohnishi Y; Tajima S; Ishibashi A
Eur J Dermatol; 2001; 11(5):420-3. PubMed ID: 11525948
[TBL] [Abstract][Full Text] [Related]
11. Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-beta in melanoma development and progression.
Malaponte G; Zacchia A; Bevelacqua Y; Marconi A; Perrotta R; Mazzarino MC; Cardile V; Stivala F
Oncol Rep; 2010 Jul; 24(1):81-7. PubMed ID: 20514447
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases MMP-1, MMP-2, and MMP-13 are overexpressed in primary nodular melanoma.
Zamolo G; Grahovac M; Žauhar G; Vučinić D; Kovač L; Brajenić N; Grahovac B
J Cutan Pathol; 2020 Feb; 47(2):139-145. PubMed ID: 31677173
[TBL] [Abstract][Full Text] [Related]
13. Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma.
Vihinen P; Koskivuo I; Syrjänen K; Tervahartiala T; Sorsa T; Pyrhönen S
Melanoma Res; 2008 Aug; 18(4):268-73. PubMed ID: 18626311
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
15. Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay.
Wollina U; Karte K; Hipler UC; Knöll B; Kirsch K; Herold C
J Cancer Res Clin Oncol; 2000 Feb; 126(2):107-10. PubMed ID: 10664251
[TBL] [Abstract][Full Text] [Related]
16. Gallic acid inhibits the migration and invasion of A375.S2 human melanoma cells through the inhibition of matrix metalloproteinase-2 and Ras.
Lo C; Lai TY; Yang JS; Yang JH; Ma YS; Weng SW; Lin HY; Chen HY; Lin JG; Chung JG
Melanoma Res; 2011 Aug; 21(4):267-73. PubMed ID: 21734530
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases in human melanoma.
Hofmann UB; Westphal JR; Van Muijen GN; Ruiter DJ
J Invest Dermatol; 2000 Sep; 115(3):337-44. PubMed ID: 10951266
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinase-2 and -9 and membrane-type 1 matrix metalloproteinase in melanocytic tumors of dogs and canine melanoma cell lines.
Docampo MJ; Cabrera J; Rabanal RM; Bassols A
Am J Vet Res; 2011 Aug; 72(8):1087-96. PubMed ID: 21801067
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
[TBL] [Abstract][Full Text] [Related]
20. The membrane tethered matrix metalloproteinase MT1-MMP at the forefront of melanoma cell invasion and metastasis.
Thakur V; Bedogni B
Pharmacol Res; 2016 Sep; 111():17-22. PubMed ID: 27221755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
